Active

GlaxoSmithKline Biologicals

Switched

BE0440872918

Rechtspersoon Public limited company 5 establishments

Rue de l'Institut 89, 1330 Rixensart Vervaardiging van geneesmiddelen

Active for

36 year, 2 months

Financials

Financial year 2025

Worth noting

  • Little cash and receivables against the short-term debts.

Revenue

€ 7,439.8 million

▼ 5% vs 2024

Profit

Growing

€ 2,396.6 million

▲ 9% vs 2024

Debts

Low

€ 7,238.9 million

▲ 72% vs 2024

GlaxoSmithKline Biologicals from Rixensart, company number BE0440872918, closed financial year 2025 with a result of € 2,396.6 million after tax. For that financial year GlaxoSmithKline Biologicals recorded revenue of € 7,439.8 million and equity of € 9,976.1 million. Compared with financial year 2024, the result moved from € 2,193.1 million to € 2,396.6 million. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 10, 2026.

What happened at GlaxoSmithKline Biologicals?

What happened at GlaxoSmithKline Biologicals in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • New annual accounts for financial year 2025: profit of € 2,396.6 million (▲ 9% vs 2024). Source: NBB ↗
  • Regis SIMARD stepped down as director. NBB
  • Aglaé VAN GOETHEM stepped down as director. NBB
  • Cristelle NOIRHOMME stepped down as director. NBB
  • Benoît ALSTEENS stepped down as director. NBB
  • Pascal LEGRAIVE stepped down as director. NBB
  • Dominique DESCAMPS stepped down as director. NBB
  • Emmanuel FELIX stepped down as director. NBB

In short

From € 455.6 million profit in 2021 to € 2,396.6 million profit in 2025.

Paid € 1,072.5 million in corporate taxes since 2021.

Best year ever: 2023, with € 3,172.8 million profit.

Paid out € 12,804.7 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at GlaxoSmithKline Biologicals? We notify you, reason included.

Follow GlaxoSmithKline Biologicals

Need more data?

History

Every financial year, as far back as the National Bank goes.

Buffer

How long does the company survive without income?

Credit limit

Indicative credit limit, computed from the real figures.

Alerts

New annual account: profit halved. New
Gazette: capital increase of 250k. New

News about who you follow, reason included.

Databakkes Pro · first month free

Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.

Management

SETFIRST LIMITED S. Etr. 56.6%
GLAXOSMITHKLINE LLC S. Etr 20.4%
GlaxoSmithKline Biologicals
GSK INTERNATIONAL LTD 100%
GLAXOSMITHKLINE BIOLOGICALS S.A.S. 100%
SMITHKLINE BEECHAM INVESTMENTS 45%
GLAXOSMITHKLINE BRAZIL LIMITADA 39.6%

The shares are held by SETFIRST LIMITED S. Etr. (56.6%) and GLAXOSMITHKLINE LLC S. Etr (20.4%). It owns 100% of GSK INTERNATIONAL LTD, 100% of GLAXOSMITHKLINE BIOLOGICALS S.A.S., 45% of SMITHKLINE BEECHAM INVESTMENTS and 39.6% of GLAXOSMITHKLINE BRAZIL LIMITADA itself.

See the full network in the app

Directors

According to the 2025 annual accounts

Emmanuel AMORY

Managing director

since 2025 · until 2025

Jamila LOUAHED

Managing director

since 2025 · until 2026

Regis SIMARD

Director

since 2025 · until 2026

Aglaé VAN GOETHEM

Director

since 2025 · until 2026

Cristelle NOIRHOMME

Director

since 2025 · until 2026

Benoît ALSTEENS

Director

since 2025 · until 2026

Pascal LEGRAIVE

Director

since 2025 · until 2026

Dominique DESCAMPS

Director

since 2026 · until 2026

Emmanuel FELIX

Managing director

since 2025 · until 2026

Irène RAPILLY

Director

since 2025 · until 2026

Shareholders

SETFIRST LIMITED S. Etr.

56.6%

GLAXOSMITHKLINE LLC S. Etr

20.4%

Participations

GSK INTERNATIONAL LTD

100%

GLAXOSMITHKLINE BIOLOGICALS S.A.S.

100%

SMITHKLINE BEECHAM INVESTMENTS

45%

GLAXOSMITHKLINE BRAZIL LIMITADA

39.6%

Establishments

Establishment units

Physical locations of this company

Registered office

Rue de l'Institut 89

1330 Rixensart

2.151.097.239

Avenue Fleming 20

1300 Wavre

Active since 1 June 2005

2.151.097.734

Rue Louis Genonceaux,Isnes 13

5032 Gembloux

Active since 1 June 2005

2.160.129.127

Avenue Pascal 2-4-6

1300 Wavre

Active since 1 January 2007

2.263.209.740

Kunstlaan 44

1040 Brussel

Active since 15 October 2015

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number
0440.872.918
VAT number
BE 0440.872.918
Registered office
Rue de l'Institut 89, 1330 Rixensart
Names & denominations
GlaxoSmithKline Biologicals · GSK Biologicals - SmithKline Beecham Biologicals
Enterprise type
Rechtspersoon
Legal form
Public limited company
Legal situation
Normale toestand
Start date
1 July 1990
Peppol
Active · Active since 6 Jul 2026
Activities · NACE

Vervaardiging van geneesmiddelen

View on CBE Public ↗ Annual accounts (NBB) ↗

Frequently asked questions

What is the enterprise number of GlaxoSmithKline Biologicals?
The enterprise number of GlaxoSmithKline Biologicals is BE0440872918.
What is the address of GlaxoSmithKline Biologicals?
The registered office of GlaxoSmithKline Biologicals is located at Rue de l'Institut 89, 1330 Rixensart.
When was GlaxoSmithKline Biologicals founded?
GlaxoSmithKline Biologicals was founded on 1 July 1990.
What is the main activity of GlaxoSmithKline Biologicals?
The main activity of GlaxoSmithKline Biologicals is "Vervaardiging van geneesmiddelen" (NACE code 21201).
Does GlaxoSmithKline Biologicals have a website?
No website is currently known for GlaxoSmithKline Biologicals.
How much profit did GlaxoSmithKline Biologicals make in 2025?
GlaxoSmithKline Biologicals posted a profit after taxes of € 2,396,619,884 in financial year 2025.
What is the revenue of GlaxoSmithKline Biologicals?
In its most recent annual accounts (2025), GlaxoSmithKline Biologicals reported revenue of € 7,439,791,208.
How many employees does GlaxoSmithKline Biologicals have?
According to the 2025 annual accounts, GlaxoSmithKline Biologicals has 8,371 full-time equivalents (FTE).
Where can I find the annual accounts of GlaxoSmithKline Biologicals?
GlaxoSmithKline Biologicals files its annual accounts with the Central Balance Sheet Office of the National Bank of Belgium. The key figures for recent financial years are available for free on this page.
Who are the directors of GlaxoSmithKline Biologicals?
According to the 2025 annual accounts, the directors of GlaxoSmithKline Biologicals are: Emmanuel AMORY, Jamila LOUAHED, Regis SIMARD, Aglaé VAN GOETHEM, Cristelle NOIRHOMME, Benoît ALSTEENS, Pascal LEGRAIVE, Dominique DESCAMPS.
Who owns GlaxoSmithKline Biologicals?
The shares are held by SETFIRST LIMITED S. Etr. (56.6%) and GLAXOSMITHKLINE LLC S. Etr (20.4%). It owns 100% of GSK INTERNATIONAL LTD, 100% of GLAXOSMITHKLINE BIOLOGICALS S.A.S., 45% of SMITHKLINE BEECHAM INVESTMENTS and 39.6% of GLAXOSMITHKLINE BRAZIL LIMITADA itself.
Who are the shareholders of GlaxoSmithKline Biologicals?
According to the 2025 annual accounts, the shareholders of GlaxoSmithKline Biologicals are: SETFIRST LIMITED S. Etr. (56.6%), GLAXOSMITHKLINE LLC S. Etr (20.4%).